Abstract.
Insulin and lipid metabolism were studied in seven patients (19±1 years) with end-stage renal disease on continuous cycling peritoneal dialsysis (CCPD) before and after 6 months of therapy with human recombinant erythropoietin (EPO) to correct anemia. Hematocrit increased from 22.2±1.8% to 34.8±1.8% (P<0.001) following EPO treatment. Serum ferritin (P<0.05) and serum iron (P<0.01) decreased significantly after anemia correction. There were no significant differences in the height, weight, anthropometric measures, or intakes of protein and total calories in the patients before and after the 6 months of EPO therapy. There were no differences in serum biochemical parameters, including 1,25-dihydroxyvitamin D3 and parathyroid hormone in these patients before and after 6 months of EPO therapy. Residual renal function and Kt/Vurea were also not different before and after 6 months of EPO therapy. The hyperinsulinemic euglycemic clamp technique was used to measure insulin sensitivity. Before EPO, insulin sensitivity was low in patients on CCPD (238±19 mg/m2 per min) compared with controls (320±30; P<0.01). After 6 months of EPO therapy, insulin sensitivity increased by 28% (305±26, P<0.01 vs. pre-EPO values), so that these values were no longer different from control values. The hyperglycemic clamp technique was used to measure insulin secretion. Before EPO, both early- and late-phase insulin secretion were elevated in patients on CCPD compared with controls (P<0.01 in both cases). These indices of insulin secretion decreased significantly (P<0.01) following 6 months of EPO. Before EPO, plasma triglycerides, total cholesterol, low-density lipoprotein, cholesterol, and apolipoprotein B were elevated in patients compared with controls. These lipid concentrations decreased significantly following 6 months of EPO. Thus, treatment of anemia by EPO is associated with improvements in insulin and lipid abnormalities in uremic patients on CCPD.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Author information
Authors and Affiliations
Additional information
Received September 23, 1997; received in revised form January 20, 1998; accepted January 22, 1998
Rights and permissions
About this article
Cite this article
Mak, R. Metabolic effects of erythropoietin in patients on peritoneal dialysis. Pediatr Nephrol 12, 660–665 (1998). https://doi.org/10.1007/s004670050524
Issue Date:
DOI: https://doi.org/10.1007/s004670050524